ArticleCancer reports (Hoboken, N.J.)2025
Association Between the Volume Transfer Constant (K
Article in Cancer reports (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Dynamic Contrast-Enhanced MRI in Neuro-Oncology: A Narrative and Translational Review.Brain sciences · 2026Review
- Association Between the Volume Transfer Constant (KCancer reports (Hoboken, N.J.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWith the development of new human epidermal growth factor 2 (HER2)-targeting therapies, a non-invasive method of determining the HER2 status of breast cancer brain metastases can be of great clinical value, particularly given the risks of brain biopsy and the possibility of discordance between HER2 status of the primary breast cancer and the brain metastasis.
aimsThe purpose of this study was to assess whether the volume transfer constant (Ktrans) from dynamic contrast-enhanced (DCE) perfusion brain MR could assist in identifying the HER2 status of breast cancer brain metastases.
methodsWith IRB approval for this retrospective study, we searched the electronic medical record at the City of Hope Comprehensive Cancer Center to identify all histopathologically proven breast cancer brain metastases with both preoperative DCE perfusion brain MR and HER2 assessment of the resected/biopsied brain specimens at the City of Hope Comprehensive Cancer Center from 2011-2022. Mann-Whitney tests were used to compare the Ktrans of the breast cancer brain metastases.
resultsThere were 9 women in our study cohort with a mean age of 55 years. Our cohort was comprised of a total of 9 breast cancer brain metastases, 3 of which were HER2-positive, 6 of which were HER2-negative. The Ktrans of HER2-positive breast cancer brain metastases was significantly greater than the Ktrans of HER2-negative breast cancer brain metastases (0.09 min
conclusionKtrans may help to differentiate HER2-positive from HER2-negative breast cancer brain metastases, if validated in a large prospective, multi-center trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.